Radiation Treatment of Lymph Node Recurrence From Prostate Cancer : is 11C-choline PET/CT Predictive of Survival Outcomes?

Completed

• Conditions: Prostate Cancer

• Registration Number: NCT06170164
• Lead Sponsor: IRCCS San Raffaele

Brief Summary

The role of PET/CT with Choline in the restaging of prostatic disease is now universally recognized, and its use has become routine in numerous centers in Italy and abroad. The indication for the test is provided exclusively by an increase in PSA. It was interesting to understand whether these prognostic factors have an influence on the probability of detecting disease by PET with Choline to identify patients who have a greater probability of benefiting from the use of this method with the possibility of identifying the disease in earlier stages.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-10-08
• Primary Completion: 2015-11-25
• Study Completion: 2015-11-25
• Study First Submitted: 2023-11-28
• Status Verified: 2023-12
• Study First Submitted QC: 2023-12-06
• Last Update Submitted: 2023-12-06
• Study First Posted: 2023-12-14
• Last Update Posted: 2023-12-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 68

Inclusion Criteria

• patients operated with radical prostatectomy
• patients that present biochemical recurrence of the disease;

Exclusion Criteria

• patients <18 years

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PET/CT with Choline in the restaging of prostatic disease.	1 year	retrospective analysis of 68 patients with biochemical recurrence of prostase disease that performed PET/CT with choline for the restaging of the disease.

Trial Locations

Locations (1)

Irccs San Raffaele; 🇮🇹 Milano, Italia, Italy